FAP and nervous system disorder: Inotersen slowed the course of neurologic disease and improved quality of life in patients with ATTRv-PN, with better results when started early.110Inotersen has been approved by ANVISA for the treatment of ATTR-FAP but so far has not been incorporated by the SUS.